Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDRX-42 in Advanced GIST
NCT05489237Phase 1Active, not recruiting
- Sponsor
- IDRx
- Start
- Aug 2022
- Primary completion
- Mar 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 1, open-label trial of IDRX-42 in gastrointestinal stromal tumor (GIST) (5 arms), sponsored by IDRx. Primary endpoints: Dose-Limiting Toxicities at 18 months, Maximum Tolerated Dose and/or Recommended Phase 1b Dose at 18 months and 3 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05489237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05489237.